NCT01435395

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme. Patients requiring anti-epileptic medications will have to be at least 10 days off EIAEDs. Only non-EIAEDs are accepted.

Conditions

• Glioblastoma Multiforme

Interventions

Type	Name	Description
DRUG	Temozolomide, bevacizumab and bortezomib	Escalating temozolomide with standard dose bevacizumab and bortezomib

Timeline

• Start date: 2011-12-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2011-09-16
• Last updated: 2016-04-27

Locations

2 sites across 1 country: United States